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Introduction
Duchenne muscular dystrophy (DMD) is an inherited muscle disease characterized by the absence of dystrophin in the membrane-associated cytoskeleton of muscle fibers. [1] [2] [3] [4] Dystrophin is associated with a large oligomeric complex of glycoproteins called dystrophin-associated proteins (DAPs) which provide linkage to the extracellular matrix. [5] [6] [7] [8] [9] The lack of dystrophin in dystrophic muscle and consequent absence of all the DAPs disrupt the linkage between the subsarcolemmal cytoskeleton and the extracellular matrix, [7] [8] [9] resulting in muscle fiber necrosis and progressive muscle weakness. [10] [11] [12] The mdx mouse, an animal model for DMD, also lacks dystrophin and DAPs in skeletal muscle fibers. 1, 13, 14 Transplantation of normal myoblasts into dystrophindeficient muscle has the potential of creating a reservoir of normal myoblasts that are capable of fusing with dystrophic muscle fibers and restoring dystrophin. 15 Animal experiments [16] [17] [18] [19] [20] [21] have shown that the transplantation of normal myoblasts results in dystrophin expression at the muscle fiber plasma membrane and subsequently improves the structure and function of dystrophic mouse muscle. However, long-term dystrophin expression following myoblast transplantation has been primarily hindered by immune rejection. Prolonged efficacy of myoblast transplantation was only observed in immunodeficient nude and SCID mice 22, 23 and mice that were adequately immunosuppressed using FK-506. 24 The initial clinical trials of myoblast transfer to DMD patients were unsuccessful, but those studies did demonstrate the transient restoration of dystrophin-positive muscle fibers in the injected DMD patients. [25] [26] [27] [28] [29] [30] [31] Although other limitations may not be excluded, 28, 31 the failure of myoblast transfer in these clinical trials was due, in part, to immune rejection. This hypothesis was supported by the detection of serum antibodies against the injected cell antigens, such as dystrophin and dystrophin-associated proteins, in some DMD patients following transplantation. 27 However, in mdx mice the restoration of dystrophin expression was not sufficient to induce an immunological rejection when fully histocompatible donors and recipients were used. 32 Experimental approaches to muscle gene therapy based on the direct injection of nonviral and viral vectors have also had only limited success. Intramuscular injection of naked or complexed DNA (liposomes) carrying reporter genes or dystrophin constructs have been relatively inefficient. [33] [34] [35] Retroviral vectors are capable of introducing truncated dystrophin to dystrophic myoblasts in vitro, but are unable to efficiently transduce differentiated muscle cells such as myotubes and myofibers, since they require dividing cells for integration and expression. 36, 37 While adenovirus (AV) appears to be a relatively good vector for skeletal muscle cells, there are potential limitations to the use of AV as a gene delivery vector to muscle, ie the differential transducibility of myofibers throughout muscle maturation; the immune rejection induced by first generation adenoviral vectors; and the high titer of viral recombinants that is often required for successful muscle transduction. [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] Recent studies with mutant AV vectors in which all viral genes were removed, suggest that these vectors may be able to circumvent the immunological problems due to viral antigens. [48] [49] [50] [51] Finally, it has also been observed, that the replication-defective herpes simplex virus type 1 (HSV-1) vector can efficiently infect and express a foreign reporter gene in muscle cells in vitro and in newborn myofibers in vivo. Limitations to the use of first generation HSV-1 vector for muscle include inefficient transduction of mature myofibers, cytotoxicity and immune rejection. [52] [53] [54] A third approach to gene complementation in skeletal muscle has been investigated: ex vivo gene transfer which consists of a combination of myoblast transplantation and gene therapy. It has been shown that isogenic myoblasts transduced with adenovirus 55 and retrovirus 56 in vitro, are capable of delivering reporter genes to muscle and the transgene expression has been found to persist for at least 1 month.
In the present study, we have evaluated for the first time the feasibility of myoblast-mediated ex vivo gene transfer of full-length dystrophin in mdx mice. We have infected myoblasts which were not capable of producing dystrophin with an adenoviral vector lacking all the viral genes but expressing full-length dystrophin and ␤-galactosidase 48 and then evaluated the ability of these transduced myoblasts to restore dystrophin protein in mdx muscle.
Results
Full-length dystrophin was delivered to mdx skeletal muscle using three different types of myoblasts Myoblasts used for our study included primary myoblasts isolated from mdx skeletal muscle and an mdx cell line with indefinite proliferative capacity due to the inclusion of a thermolabile immortalizing gene. 57 These myoblasts were transduced with a high capacity adenoviral vector (AdDYS␤gal) that expresses both the fulllength murine dystrophin cDNA under the control of a muscle creatine kinase (MCK) promoter, and the lacZ gene under the control of a human cytomegalovirus (HCMV) promoter. 48 Both the primary mdx myoblasts and the immortalized mdx cell line were capable of expressing ␤-galactosidase in vitro following infection with adenoviral vector (AdDYS␤gal). To obtain similar levels of transduction in both types of myoblasts, we used a multiplicitiy of infection of 10 (MOI = 10) for primary myoblasts, and MOI = 25 for the immortalized cell line. The percentage of transduced myoblasts was not significantly different (P = 0.9908) in either type of myoblast (primary mdx (38 ± 3%) and immortalized mdx cell line (31 ± 4%) ). We observed that both vector-transduced primary mdx myoblasts and the vector-transduced immortalized mdx cell line were capable of fusing to form differentiated myotubes expressing both full-length dystrophin and ␤-galactosidase in vitro (data not shown).
A third cell line used for our study was an immortalized myogenic line (MTMD cells; SD Hauschka, unpublished data) derived from transgenic mdx mouse muscle that overexpresses dystrophin (approximately 50-fold) under the control of the MCK promoter. 58 These MTMD myoblasts were also capable of differentiating into myotubes and expressing high levels of dystrophin in vitro.
A schematic representation of the myoblast mediated gene transfer procedures used in our studies is shown in Figure 1 . The primary mdx and the immortalized mdx cell lines were utilized as vehicles for myoblast mediated ex vivo gene transfer. The MTMD cell line was used for direct myoblast transfer. The mdx muscle which received myoblast transplantation was irradiated 2 days before transplantation and destroyed with notexin 1 day before injection of either 1 × 10 6 adenoviral vector-transduced or 1 × 10 6 MTMD myoblasts. The treated muscles were collected 5, 10, 20 and 25 days following transplantation.
Muscles transplanted with the vector-transduced immortalized cell line ( Figure 2 ) and with the vectortransduced primary mdx myoblasts ( Figure 3 ) demonstrated the presence of muscle fibers expressing ␤-galactosidase (Figures 2a and 3a) and full-length dystrophin (Figures 2b and 3b) at the injection site. The colocalization of dystrophin and fluorescent latex microspheres (FLMs) (Figures 2c and 3c ) indicated that the dystrophinpositive myofibers were formed by the fusion of the injected myoblasts rather than from a somatic reversion of the mdx phenotype. 59 Muscles transplanted with MTMD myoblasts showed significantly more dystrophin-expressing muscle fibers in cryostat sections made through the site of injection than sections from muscles transplanted with either transduced primary mdx myoblasts or the transduced immortalized mdx cell line at 5 days after injection (Table 1 and Figure 4a ). The low percentage of transduction in the primary and immortalized mdx myoblasts in vitro may account for this differential level of gene transfer between the MTMD and the primary, immortalized mdx cell line. As observed with the vector-transduced primary mdx and immortalized cell line, colocalization of dystrophinexpressing muscle fibers with FLMs indicated that the dystrophin-positive staining was derived from the fusion of the injected MTMD myoblasts (Figure 4b ).
To clarify whether engineered myoblasts, which were capable of expressing high levels of dystrophin, might be beneficial for dystrophin gene transfer to dystrophic muscle, we compared the efficiency of dystrophin delivery by the MTMD cell line with that of normal primary muscle cultures derived from C57BL10+/+ mice. By identifying myoblasts via their desmin-positive staining characteristics, these cultures contain 30-40% myoblasts and 60-70% fibroblasts. Mdx leg muscles injected with equal numbers of MTMD and primary cells contained approximately 30 times more dystrophin-positive myofibers when injected with the MTMD myoblasts. Presumably the relatively low percentage of myoblasts in the primary cultures accounts for much of the differential transduction between the two cell lines. This was confirmed by comparing the efficiency of gene transfer between the MTMD myoblast cell line and an equivalently pure spontaneously transformed normal mouse myoblast cell line (ATCC, Rockville, MD, USA). In this comparison the MTMD-injected mdx muscles contained only a three-fold greater abundance of dystrophinpositive myofibers than obtained with the C57BL10+/+ myoblasts. Collectively, these results suggest that dystrophin overexpression by the injected myoblasts provides at least some beneficial effect with respect to the percentage of dystrophin-positive myofibers obtained. However, the purity of the injected cells with respect to their myoblast content is also beneficial. Characterization of the persistence of transgene expression mediated by the ex vivo gene transfer approach We observed a marked decrease in the number of transduced myofibers at 25 days after injection in muscle injected with immortalized mdx myoblasts transduced in vitro with AdDYS␤gal ( Figure 6a ). In fact, rare ␤-galactosidase expressing myofibers were found in injected muscle and were infiltrated with many mononucleated cells ( Figure 6b ). To clarify the nature of these mononucleated cells, we characterized by immunoperoxidase the presence of activated lymphocytes in injected muscle. 
Massive infiltration with CD4
+ and CD8 + activated lymphocytes was observed in muscle injected with either immortalized (Figure 6c and d) or primary mdx myoblasts ( Figure 6e and f) at 10 and 5 days after injection respectively. The colocalization of these activated lymphocytes with FLMs showed that infiltration of mononucleated cells is located at the injection site.
Direct adenoviral delivery of dystrophin was less efficient than myoblast-mediated delivery Table 1 shows the number of dystrophin-positive myofibers detected at 5 days after injection in muscle sections of the mdx muscles following myoblast-mediated gene delivery and adenovirus-mediated direct gene transfer. The efficiency of gene transfer mediated by MTMD myoblasts, transduced primary myoblasts, transduced immortalized mdx myoblasts and direct inoculation of the adenoviral vector differed in the number of dystrophin-positive myofibers seen in the injected mdx muscles. The number of dystrophin-expressing myofibers after transplantation with vector-transduced primary mdx and vector-transduced immortalized cell line was not significantly different (P = 0.654). MTMD cells produced at least seven times more dystrophin-positive myofibers at the injected site than an injection of the same amount of transduced primary mdx myoblasts and the immortalized mdx cell line (P Ͻ 0.05). In addition, the number of transduced myofibers obtained using the ex vivo approach was significantly higher than that obtained after the direct injection of the same adenoviral solution (P Ͻ 0.05). The number of dystrophin-expressing myofibers obtained following direct adenovirus gene transfer in destroyed mdx muscles following irradiation versus without irradiation (four versus five) was not found to differ significantly (P = 0.057). Finally, the level of dystrophin-positive myofibers obtained following the direct injection of the same number of AdDYS␤-gal adenovirus particles (1 × 10 7 ) used to infect 1 × 10 6 primary myoblasts injected in the ex vivo gene transfer studies did not differ significantly from the number of revertant myofibers present in the contralateral, noninjected gastrocnemius muscle (four versus six, P = 1.238; five versus six, P = 0.764).
Discussion
The present study was undertaken to provide a model system for testing the feasibility of autologous myoblast transfer as a technique for gene complementation for Duchenne muscular dystrophy (DMD). Since a major impediment facing the application of gene therapy to skeletal muscle is the inability of many viral vectors to efficiently transduce mature myofibers directly, we tested the ability of myoblast mediated ex vivo gene transfer to deliver full-length dystrophin to adult mdx muscle. The level of gene transfer mediated by the ex vivo approach has been compared with that achieved by the direct injection of the same amount of the viral vector.
We show that myoblasts could be transduced in vitro using a high capacity adenoviral vector deleted for all viral genes and expressing full-length dystrophin as well as ␤-galactosidase. 48 The transduced myoblasts were capable of fusing to form myotubes expressing ␤-galactosidase in vitro. We also report the first demonstration of full-length dystrophin delivery to mature skeletal muscle using myoblast mediated ex vivo gene transfer. The efficacy of gene delivery was demonstrated 5 days after injection by the presence of myofibers expressing lacZ and dystrophin in the injected mdx muscle. The injected myoblasts were also labelled with fluorescent latex microspheres (FLMs) which provided a tag for the injected myoblasts. 60 The presence of FLMs inside dystrophin-expressing myofibers demonstrated the contribution of the injected myoblasts to the formation of those muscle fibers. 61 The gene transfer of full-length dystrophin by this approach resulted in the restoration of dystrophinassociated proteins in mdx muscle fibers. Previous studies have shown that the absence of dystrophin results in the loss of all the dystrophin-associated proteins. Here we restored the 35 kDa and ␤-43 kDa sarcoglycans in mdx muscle injected with MTMD myoblasts, transduced primary mdx myoblasts, and the transduced immortalized mdx myoblast cell line. In addition, the colocalization of these sarcoglycan-positive myofibers with FLMs suggested that these myofibers were also dystrophin-positive (see Figure 5) . Restoration of the 35 kDa and ␤-43 kDa sarcoglycans mediated by full-length dystrophin delivery in mdx muscle following ex vivo gene transfer indicated that the transferred dystrophin would probably function normally. It is likely that the restoration of dystrophin restores all the DAPs, as is demonstrated in other analogous experimental studies. 58 If so, this should stabilize the dystrophin complex and prevent muscle fiber necrosis.
We have also examined the potential value of utilizing myoblasts engineered so as to greatly overexpress dystrophin, the idea being that this might rectify the lack of dystrophin expression by DMD myonuclei in fibers formed by the fusion of both ex vivo modified and endogenous DMD myoblasts. This hypothesis was tested by injecting MTMD myoblasts, a permanent muscle cell line derived from a transgenic mdx mouse which overexpresses dystrophin 50-fold. 58 The transplantation of MTMD myoblasts resulted in a seven-fold higher level of dystrophin-positive myofibers detected in cryostat sections made through the injection site than obtained with the injection of ex vivo engineered primary or immortalized mdx cells. However, at least some of this difference could have been due to the fact that only about 40% of the ex vivo modified myoblasts were transduced by the adenoviral vector. To clarify this issue, equal numbers of MTMD myoblasts and normal myoblasts (cell line) were injected into mdx muscles and the percentage of dystrophin-positive myofibers within the injection site were compared 5 days after injection. In this case a three-fold higher level of dystrophin-positive myofibers was observed in muscle injected with MTMD cells than injected with normal myoblasts. This is consistent with a previous study which reported that engineered myoblasts containing multiple copies of dystrophin could enhance the efficiency of gene delivery to muscle, but only a three-to four-fold larger nuclear domain was observed. 62 The inability of dystrophin to efficiently diffuse from the expressing nuclei 62 may explain why myoblasts engineered to express 50 times the normal level of dystrophin lead to a three-fold increase in the number of dystrophin-positive myofibers.
In our study, the host muscle was stimulated to undergo regeneration by the injection of notexin, a myonecrotic agent that causes necrosis and the subsequent regeneration of numerous myofibers 63 in the vicinity of the injection site. In addition, the host muscle was irradiated in order to prevent many of the host satellite cells from participating in muscle regeneration. 15, 17 The rationale for the irradiation and artificial induction of muscle regeneration is to allow a better participation of the injected myoblasts in muscle regeneration. The injection of myoblasts into mdx muscle without irradiation and destruction also leads to gene complementation by the injected myoblasts, but the efficiency of gene transfer is decreased when compared with the results of the same injection into irradiated and destroyed muscle.
Two types of dystrophin-positive myofibers containing FLMs were found in the injected muscle at 5 days after injection (large and small diameter dystrophin-positive myofibers). The small diameter muscle fibers are likely to be regenerating muscle fibers that were formed exclusively by the fusion of the injected myoblasts. The large diameter dystrophin-positive myofibers containing FLMs are likely to be mosaic muscle fibers formed by the fusion of the injected myoblasts with the host myofibers that survived notexin treatment. Similar observations were previously reported following xeno-transplantation. 23 This study demonstrates that the myoblast mediated ex vivo approach possesses many attributes that may make it useful for effective gene transfer to skeletal muscle. One benefit of using myoblasts as a vehicle for gene complementation for DMD is their ability to transfer genes to mature muscle. In fact, the poor level of transduction in mature muscle with various viral vectors (adenovirus, retrovirus and herpes simplex virus) remains a major obstacle to the application of gene therapy for DMD. [36] [37] [38] [39] [40] [41] [42] [52] [53] [54] To compare the relative dystrophin gene transfer efficiency between dystrophin-containing adenoviral particles for direct injection with that obtained when the same adenovirus preparation is used in an ex vivo protocol, 1 × 10 7 AdDYS␤gal viral particles were either injected directly into an mdx leg muscle site, or used to infect 1 × 10 6 primary mdx muscle cells that were subsequently injected into the contralateral mdx leg muscle site. Analysis of the sites 5 days after injection indicated a nearly 10-fold greater number of dystrophin-positive muscle fibers in mdx sites treated with the ex vivo cell transfer protocol compared with that obtained via direct adenovirus injection (Table 1) . It is important to emphasize, however, that while ex vivo gene transfer to mdx skeletal muscle is more effective than direct virus injection at the comparatively low viral titer tested in our experiments, most direct adenovirus injection studies have used two to three orders of magnitude higher viral particle numbers. 41 Comparisons of ex vivo dystrophin gene transfer to that obtained by direct injection of AdDYS␤gal particles at such elevated viral levels were not made in the present study. However, a similar observation has previously been reported using higher adenoviral titers injected directly or mediated with myoblasts, 55 in adult mdx mice. Interestingly, the higher efficiency of gene transfer mediated by the ex vivo approach is achieved despite the fact that a major loss of the injected myoblasts (over 80%) was observed in the early post-injection period with the ex vivo approach. 55, 64, 65 Since adenovirus is capable of infecting myoblasts more efficiently than differentiated myotubes in vitro, it is likely that infection of myoblasts in vitro before transplantation will enhance the efficiency of the adenovirus-mediated gene transfer to mature myofibers. 42 In other studies, a higher level of transduction has been observed with adenovirus in regenerating mature muscle, where many of the myoblasts are fusing to regenerate the muscle, than in the age-matched control. 41 Finally, since many viral vectors (adenovirus, retrovirus, herpes simplex virus) are capable of efficiently infecting myoblasts, it is likely that the ex vivo technique will be a useful approach for delivering these virally transferred therapeutic genes to mature muscle. In fact, recent studies showed similar improvements in gene transfer obtained by using the ex vivo approach with other viral vectors including herpes simplex virus type 1(HSV-1) 66 and retrovirus. 67 A secondary benefit in the use of a myoblast mediated ex vivo gene transfer, is that these cells may serve not only as a vehicle for gene complementation, but also as a reservoir of myogenic cells capable of regenerating myofibers. Since muscle weakness in DMD patients is not typically noticed until approximately 5 years of age, it appears that the dystrophic muscle of younger children is functionally rescued by the large population of satellite cells that continuously regenerate the chronically damaged myofibers. As the patient ages and the satellite cells eventually undergo mitotic senescence, 68 ,69 the progressive muscle weakness associated with this disease becomes manifest. The ex vivo approach permits not only the restoration of myoblasts capable of regenerating myofibers and potentially reconstructing the dystrophic muscle, but also permits the introduction of normal cDNA copies of dystrophin to the dystrophic mdx muscle. Another potential value of the myoblast-mediated approach is the capacity of injected myoblasts to give rise to a satellite cell population capable of engaging in the repair of dystrophin deficient myofibers that may later undergo necrosis. Although our present study does not evaluate the ability of the injected myoblast to give rise to satellite cells, it has been previously reported that injected myoblasts become satellite cells. 23 The ex vivo approach could thus present an important alternative treatment, particularly for DMD patients over 10 years of age, when their myofibers become extremely inefficient in regeneration and may be refractory to direct viral transduction.
We have observed, however, that the ex vivo approach does not eliminate the risk of immunorejection that has hindered the success of direct gene transfer of replicationdefective adenovirus [43] [44] [45] [46] [47] and myoblast transfer in both animal models [22] [23] [24] and in DMD patients. 27, 29 In fact, 25 days after myoblast-mediated gene transfer, we observed massive infiltration of CD4 + -and CD8 + -activated lymphocytes in muscles injected with either the immortalized myoblast cell line or primary myoblasts which demonstrates that the lack of persistence of the transgene expression with the ex vivo approach is attributed to immunorejection (see Figure 6 ). The lack of persistence of the transgene expression with both immortalized and primary myoblasts suggests that the immunorejection may be induced by viral proteins, ␤-galactosidase or dystrophin expression. Previous studies of direct gene transfer of AdDYS␤gal or first generation adenoviral vector expressing ␤-galactosidase showed that the expression of ␤-galactosidase from the adenoviral vector is highly immunogenic. 70, 71 In fact, persistence of transgene expression from AdDYS␤gal was observed in a transgenic mouse endogenously expressing ␤-galactosidase. 70 The contribution of different antigens to this immunorejection induced by myoblast-mediated gene delivery is under investigation in our laboratory. Since, stable transgene expression over a 1-month period was observed in animal models with both approaches (myoblast transfer and gene therapy based on adenovirus) using FK506 immunosuppressive treatment 24, 72 that blocked the cellular infiltration and the humoral response, it is likely that immunosuppression may be needed to achieve long-term persistence with the ex vivo approach.
Our findings suggest that it may be possible to rescue the dystrophin-deficient myofibers of DMD patients by transducing their own myoblasts with a sufficient number of full-length dystrophin cDNA copies in vitro and subsequently transplanting them back into their own muscle. A potential drawback will be the ability to obtain a sufficient number of ex vivo modified myoblasts for injection in muscle which would be required for a beneficial level of therapy. The current goal for this therapy is to inject a sufficient number of autologous myoblasts to prevent further muscle deterioration even if this does not achieve frank functional improvement. Even though DMD satellite cells have been shown to have a limited proliferative capacity, especially those from older patients, 68 it may be possible to isolate satellite cells from less affected muscles in DMD patients to serve as a more suitable source of myoblasts for the ex vivo gene transfer. 73 Alternatively, given the success encountered in this study with the immortalized mdx cell line overexpressing dystrophin, it is possible that such cells could be produced from DMD patients.
Materials and methods
Host, donor animals and cell cultures Two different mdx myoblast cell lines were used as vehicles for the ex vivo procedures. The primary mdx myoblasts were isolated from 2-week-old mdx mice and cultivated as previously described. 22, 23, 55 The immortalized mdx cell line was isolated from a transgenic animal carrying a thermolabile SV40 T antigen under the control of an inducible promoter. 57 The immortalized mdx cell line proliferates indefinitely under permissive conditions (33°C with gamma interferon) and undergoes normal differentiation at 37-39°C without gamma interferon. 57 As positive controls for the ex vivo myoblast transfer studies we used two different sets of normal myoblasts. One set consisted of primary muscle cultures containing 30-40% myoblasts and 60-70% fibroblasts; the other set consisted of a spontaneously transformed mouse myoblast cell line (ATCC). An additional positive control consisted of the MTMD myoblast cell line. These spontaneously transformed myoblasts (S Hauschka, unpublished data) were derived from a transgenic mdx mouse strain which overproduces dystrophin about 50-fold. 58 In comparison to the two sets of normal myoblasts which overexpress normal levels of dystrophin, the MTMD myoblasts provided a means of examining the potential value of engineering host myoblasts ex vivo so as to greatly overproduce dystrophin. In all of these studies the myoblasts were injected into the gastrocnemius muscles of 4-month-old mdx mice (see below).
Adenoviral vector
The construction, propagation, purification and titration of the adenoviral vector AdDYS␤gal, carrying the fulllength murine dystrophin cDNA under the control of the muscle creatine kinase promoter (MCK) and the lacZ gene under the control of the human cytomegalovirus (HCMV) promoter were previously described. 58 The titer of the AdDYS␤gal used for these experiments was 5 × 10 10 infectious particles per milliliter. The contamination of the viral stock with helper virus is approximately 1%.
Preparation of myoblasts
The leg muscles of 2-week-old mdx mice were removed immediately after death. The primary myoblasts were isolated as previously described 55 and grown in culture for 5 days in a proliferating medium which consisted of DMEM and 15% fetal bovine serum (Gibco-BRL, Grand Island, NY, USA). For each injection, one million myoblasts were infected with AdDYS␤gal (2.5 × 10 7 infectious particles: immortalized mdx cell line, MOI = 25 and 1 × 10 7 infectious particle: primary myoblasts, MOI = 10). Fluorescent latex microspheres (0.5 m, FLMs) were added to the cultured myoblasts at a dilution of 1:1000 to label the mdx myoblasts allowing the early fate of the injected myoblasts to be followed in vivo. 60, 61 The MTMD cell line was allowed to proliferate in F-10 medium (Gibco-BRL) containing 15% horse serum and basic fibroblast growth factor (␤FGF; 4 ng/ml) and was also labelled with FLMs. At 24 h after infection the myoblasts were detached using trypsin (0.25%) for approximately 1 min. The myoblast solution was centrifuged for 5 min at 3500 r.p.m. (ෂ5 g) and the myoblast pellet was reconstituted with 25 l of Hank's balanced salt solution (HBSS; Gibco-BRL). The harvested cells were transplanted using the technique described below. Additional cultures of myoblasts and myotubes were also stained for dystrophin and lacZ reporter genes using the staining techniques also described below.
Cultures containing mixtures of normal primary myoblasts and fibroblasts were obtained using the following protocol. Muscles of the legs from newborn mice (C57BL10J+/+) were dissociated by enzymatic treatment with collagenase 0.2% for 1 h followed by a trypsin incubation (0.1%) for 30 min. The myoblasts were grown in Dulbecco's modified Eagle's medium (DMEM) containing 20% fetal bovine serum for 2 and 3 days. The mixed population of normal primary myoblasts and fibroblasts was then obtained by trypsinizing the initial primary cultures as described above for the mdx myoblasts.
Myoblast transplantation
Forty-eight hours before transplantation the gastrocnemius muscle was irradiated with gamma rays (30 Gy) to inactivate host satellite cells. Twenty-four hours before transplantation the muscle was injected with a myonecrotic agent (notexin, 0.1 g) to trigger muscle regeneration. The mdx mice were anesthetized before transplantation using 0.4 ml of a 1:1 dilution of ketamine and xylazine (Phoenix Pharmaceuticals, St Joseph, MO, USA) (both 1:9 anesthetic:saline). Then 25 l of the transduced myoblast solution (1 × 10 6 myoblasts) was injected intramuscularly into the irradiated and notexin destroyed mdx muscle. As a control for the experiment, primary normal myoblasts as well as MTMD myoblasts were injected into mdx muscle which has not been irradiated or destroyed with notexin. The injected mice were killed at 5, 10, 20 and 25 days after injection, and the gastrocnemius muscles from the injected and the noninjected legs were removed and snap frozen in isopentane precooled in liquid nitrogen. The mdx muscle was cryostat sectioned in its entirety at 10 m thickness and prepared for staining.
Intramuscular inoculation of the adenoviral vector
In other studies, 1 × 10 7 infectious particles of the adenoviral vector (the same viral particle number used to infect 1 × 10 6 primary mdx cells), were also injected intramuscularly into the destroyed gastrocnemius muscle (irradiated and nonirradiated) using a Hamilton syringe. As described above, the injected animals were killed 5 days after injection, and the injected muscles were removed and snap-frozen in isopentane pre-cooled in liquid nitrogen.
␤-Galactosidase staining ␤-Galactosidase staining was performed using a histochemical technique previously described. 74 The sectioned muscle was incubated overnight with X-gal substrate at 37°C and then counterstained with hematoxylin and eosin. 55 Immunohistochemistry staining techniques Dystrophin: Muscle sections were fixed with cold acetone (100%) for 1 min and rinsed with phosphate buffered saline (PBS) containing 0.5% Tween 20 (PBS-T). The sections were blocked with 5% horse serum in PBS for 30 min. The primary antibody used was a polyclonal rabbit anti-dystrophin (6-10 antibody) which was incubated in a 1:1000 dilution on the muscle sections overnight. After subsequent washings, the sections were incubated with a goat anti-rabbit antibody conjugated to biotin in a 1/500 dilution for 1 h (Vector Laboratories, Burlingame, CA, USA). After removal of the secondary antibody the sections were again rinsed in PBS-T and finally incubated with streptavidin-fluorescein (FITC) at a dilution of 1:100 for 1 h (Vector Laboratories). The slides were then mounted and observed using fluorescent microscopy (Nikon).
Dystrophin-associated proteins (35 kDa, ␤-43 kDa): Serial muscle sections from mdx-injected muscles were also used for dystrophin-associated protein labelling (sarcoglycan 35 kDa and ␤-43 kDa). The sections were fixed with cold acetone (100%) for 1 min and incubated for 30 min with horse serum (10%). They were then incubated overnight with a rabbit polyclonal antibody against the DAP 35 kDa at a dilution of 1:500 75 or with a guinea pig polyclonal antibody anti-43 kDa sarcoglycan at a dilution of 1:500 76 for 1 h. Following several rinses in PBS-T, the muscle sections were incubated with a biotinylated goat anti-rabbit antibody (Vector Laboratories; 1:2500) or biotinylated goat anti-guinea pig antibody (Sigma BioSciences, St Louis, MO, USA; 1:500) for 1 h. Finally, the sections were incubated with streptavidin conjugated fluorescein (1:500) for 45 min (Vector Laboratories). The sections were then mounted in gel mount (Biomeda, Foster City, CA, USA) and observed under fluorescent microscopy (Nikon, Melville, NY, USA). Muscle sections for dystrophin, dystrophin-associated proteins, and ␤-galactosidase staining were viewed under light microscopy and epifluorescence (Nikon), digitized with a video camera (Optronics DEI-750, Goleta, CA, USA) and frame grabber. The images were then printed on a color printer (Codonics NP 1600, Middleburg Heights, OH, USA).
Detection of CD4-and CD8-activated lymphocytes
The lymphocytes were detected following a protocol previously described by Larsson et al. 77 The muscle sections were first fixed with cold acetone for 10 min and the nonspecific binding site was blocked with a mixture of goat and horse serum (3%) for 10 min followed by rinses with PBS. The primary antibodies used were a rat monoclonal antibody against CD4 (Pharmingen, San Diego, CA, USA) and CD8 (Pharmingen) for 2 h at room temperature. Subsequently, the endogenous peroxidase activity was blocked with 1% hydrogen peroxide for 20 min. Following several rinses in PBS, the sections were incubated with a biotinylated goat anti-rat antibody (Dako, 1/500) for 1 h. This was followed by several rinses in PBS and finally incubated with Vectastain Elite ABC (5 ml PBS + two drop A and B; Vector) for 30 min. The peroxidase activity was revealed using 3′,3′-diaminobenzidine (1 mg/ml; Sigma) and hydrogen peroxide (0.03%). Muscle sections were then mounted in Gel Mount (Biomeda) and visualized by light and fluorescence microscopy (Nikon; Optiphot microscope).
Statistical analysis
Differences noted between the number of dystrophinpositive myofibers obtained following the different gene transfer techniques were determined by one-factor analy-sis of variance (multi-comparison experiment type factorial) using a statistical software package (Stat View 512 + ; Brain Power, Calabasas, CA, USA). The numbers of transduced myofibers in all groups were expressed as means ± standard deviation. The comparison of the number of dystrophin-positive muscle fibers within the different gene transfer techniques was performed using Fisher's least-significant difference test. Statistical significance was defined as P Ͻ 0.05 versus the number of transduced myofibers obtained using the ex vivo approach using primary mdx myoblasts (see Table 1 ). The comparison of the number of dystrophin-expressing myofibers obtained following direct adenovirus gene transfer in mdx muscle, with or without irradiation, and the number of revertant fibers expressing dystrophin in control noninjected muscle from the contralateral leg of the experimental mice was also compared.
